Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Major Factor in the Transformation of the Avastin (Bevacizumab) Market in 2025

What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market?
In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase in cancer cases, adoption by clinicians, the expansion of indication approvals, and favourable reimbursement policies.

The market size for avastin (bevacizumab) is projected to experience significant expansion in the upcoming years, increasing to $10,488.97 million in 2029 with a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period is likely due to enhanced awareness and early detection, competitiveness in biosimilars, development in personalized medication, better access to healthcare, and a rising focus on precision medicine. Key trends for the forecast period encompass the growth in combination therapies, a move towards outpatient care, patient-centered treatment approaches, the use of targeted therapies, and innovation in products.

What Is Contributing to the Growth of the Avastin (Bevacizumab) Market?
The avastin (bevacizumab) market is anticipated to expand due to the rising incidence of cancer. Referring to a variety of diseases classified by abnormal cell growth and distribution throughout the body, the term 'cancer' is broad. Factors causing the soar in prevalence include lifestyle alterations, improved diagnostic methods, and an aging population. Avastin hinders cancer growth by stopping the establishment of blood vessels that feed tumors with oxygen and nutrients. For instance, the American Cancer Society forecasts around 1.9 million new cancer instances and 609,360 cancer-related deaths in the USA in 2022, equating to around 1,670 deaths daily. Hence, the surge in cancer cases is catalyzing the avastin (bevacizumab) market's growth. Increasing healthcare expenditure is also predicted to boost the avastin (bevacizumab) market's growth. This term encompasses all spending on health-related products and services aimed at fostering better health outcomes. Several factors, such as aging populations, chronic diseases, high medicinal costs, inefficient payment structures, and growing demand for services, are contributing to the ballooning healthcare expenditure. This expenditure increase facilitates improved access to Avastin (bevacizumab) through insurance schemes. For instance, the UK's Office For National Statistics reported an increase of 5.6% in overall healthcare expenditure between 2022 and 2023, which was an increase from the 0.9% growth rate in 2022. There was also a rise of 2.8% in long-term health and social care expenditure in 2022 in real terms. Therefore, the increasing healthcare costs are fueling the advancement of the avastin (bevacizumab) market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19879&type=smp

Which Key Market Leaders Are Driving Avastin (Bevacizumab) Industry Growth?
Major companies operating in the avastin (bevacizumab) market include Roche Holding AG

What Are the Emerging Trends in the Avastin (Bevacizumab) Industry?
A prime trend in the avastin (bevacizumab) market revolves around the development of biosimilars, offering cost-effective alternatives and broader access to cancer therapies. Avastin biosimilars are biologic drugs that share high similarities with avastin (bevacizumab), a monoclonal antibody predominantly used in many cancer treatments, in terms of structure, efficacy, and function. These are revolutionizing cancer treatment by enhancing the availability of efficacious therapies, particularly in healthcare environments where resources are scarce. For example, Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the US, introduced ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin, into the US market in October 2022. This biosimilar is a vascular endothelial growth factor (VEGF) inhibitor implicated in oncology, and it's prescribed for various cancers, such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and numerous gynecologic cancers.

What Are the Main Segments in the Avastin (Bevacizumab) Market?
The avastin (bevacizumab)market covered in this report is segmented -

1) By Dosage: 100 Mg; 400 Mg
2) By Application: Non Squamous Non-Small Cell Lung Cancer; Recurrent Glioblastoma; Cervical Cancer; Colorectal Cell Cancer; Ovarian Cancer; Proliferative Diabetic Retinopathy; Malignant Glioma; Neurofibromatosis; Pancreatic Cancer; Other Applications
3) By Distribution channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End User: Hospitals; Cancer Supportive Centers; Home Healthcare; Academic And Research Institutes; Other End Users

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report

Which Geographic Area Leads the Avastin (Bevacizumab) Market?
North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Avastin (Bevacizumab) Global Market Report?

- Market Size Analysis: Analyze the avastin (bevacizumab) Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the avastin (bevacizumab) market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall avastin (bevacizumab) market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the avastin (bevacizumab) market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19879

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.